Suppr超能文献

使用细胞因子和基质细胞的不同组合对脐带血干细胞进行体外扩增。

Ex vivo expansion of umbilical cord blood stem cells using different combinations of cytokines and stromal cells.

作者信息

Madkaikar Manisha, Ghosh Kanjaksha, Gupta Maya, Swaminathan Suchitra, Mohanty Dipika

机构信息

Institute of Immunohaematology (ICMR), KEM Hospital, Parel, Mumbai, India.

出版信息

Acta Haematol. 2007;118(3):153-9. doi: 10.1159/000108630. Epub 2007 Sep 20.

Abstract

Umbilical cord blood is a promising source of hematopoietic stem cells (HSC) for allogeneic transplantation. However, graft rejection and delayed engraftment remain major limitations, both of which are related to a limited number of stem cells in the cord blood graft. Ex vivo expansion of HSC has been suggested as one of the ways of overcoming the challenges caused by a limited hematopoietic cell number from cord blood stem cell transplantation. In this study, we quantified and characterized an ex vivo expansion capacity of cord blood-derived HSC in a liquid culture system under different conditions. These conditions included: the combinations and concentrations of hematopoietic growth factors [stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, IL-6 and erythropoietin (EPO)], placental conditioning medium (PCM), and stromal cell support. During culture, the mean nucleated cell count, the mean CD34+ cell count, fold expansion, viability, clonogenic assays and immunophenotypic characterization were performed on day 0, day 7, day 12 and day 14 on the expanded cellular product. The maximum expansion was achieved using GF2 (SCF + IL-3 + GM-CSF) with stromal cell support. The mean CD34+ cell expansion on days 7 and 12 was 16.25- and 21.4-fold (5.2-32), respectively, and the mean nucleated cell expansion was 15.1- and 21-fold (18.1-23.2). The mean nucleated cell viability on day 12 was 87.9% (85.6-92.5). After 12 days, granulocyte-macrophage colony-forming units CFU-GEMM showed a 20.4-fold increase. A 21.4-fold increase in the CD34+ cells and a 20-fold increase in the CFU-GEMM should provide enough cells from a single cord blood unit to reduce the period of cytopenia after single unit cord blood transplantation. Even if there was some doubt about the long-term repopulating capacity of the expanded cells part of the collected umbilical cord cells (25%) could be expanded till day 12 after transplanting the major part (75%) of the collection.

摘要

脐带血是同种异体移植中很有前景的造血干细胞来源。然而,移植物排斥和植入延迟仍然是主要限制因素,这两者都与脐血移植物中干细胞数量有限有关。造血干细胞的体外扩增被认为是克服脐血干细胞移植中造血细胞数量有限所带来挑战的方法之一。在本研究中,我们在不同条件下的液体培养系统中对脐血来源的造血干细胞的体外扩增能力进行了量化和表征。这些条件包括:造血生长因子[干细胞因子(SCF)、粒细胞-巨噬细胞集落刺激因子(GM-CSF)、白细胞介素(IL)-3、IL-6和促红细胞生成素(EPO)]的组合和浓度、胎盘条件培养基(PCM)以及基质细胞支持。在培养过程中,在第0天、第7天、第12天和第14天对扩增后的细胞产物进行有核细胞计数均值、CD34+细胞计数均值、扩增倍数、活力、集落形成试验和免疫表型表征。使用GF2(SCF + IL-3 + GM-CSF)并在基质细胞支持下实现了最大扩增。第7天和第12天CD34+细胞的平均扩增倍数分别为16.25倍和21.4倍(5.2 - 32),有核细胞的平均扩增倍数为15.1倍和21倍(18.1 - 23.2)。第12天有核细胞活力均值为87.9%(85.6 - 92.5)。12天后,粒细胞-巨噬细胞集落形成单位CFU-GEMM增加了20.4倍。CD34+细胞增加21.4倍以及CFU-GEMM增加20倍应该能从单个脐血单位提供足够的细胞,以缩短单单位脐血移植后血细胞减少的时间。即使对于扩增细胞的长期重建能力存在一些疑问,在移植大部分(75%)采集物后,所采集的脐带细胞的一部分(25%)仍可扩增至第12天。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验